{"id":"W4390902638","doi":"10.1200/jco.23.01569","title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Western University; Juravinski Cancer Centre","funders":"Cilag; EMD Serono; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; AstraZeneca; EUSA Pharma; Seagen; LG Chem; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; BeiGene; Tizona Therapeutics; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Sunitinib; Clinical endpoint; Renal cell carcinoma; Internal medicine; Hazard ratio; Pembrolizumab; Discontinuation; Oncology; Phases of clinical research; Clinical trial; Confidence interval; Cancer; Sorafenib; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01500392,0.001678107,0.003901027,0.0006730513,0.0003337688,0.001734633,0.001035753,0.001252682,0.002109198],"category_scores_gemma":[0.006582596,0.0005601171,0.009010119,0.0004990308,0.0006075933,0.001230826,0.0006638182,0.003682464,0.0003805901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001389475,"about_ca_system_score_gemma":0.002436647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009121047,"about_ca_topic_score_gemma":0.003591394,"domain_scores_codex":[0.9915974,0.006538041,0.0003871187,0.0004185518,0.0006571572,0.0004018622],"domain_scores_gemma":[0.9943284,0.002555279,0.001233228,0.000517702,0.0004234381,0.0009419432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9149461,0.006174463,0.007465233,0.001199306,0.02188976,0.0001283895,0.0001449995,0.003602328,0.006704717,0.0002283423,0.002141092,0.03537528],"study_design_scores_gemma":[0.5061805,0.3832058,0.07567596,0.0002287609,0.01977802,0.000268041,0.0001387502,0.005414102,0.004100354,0.0007031349,0.004224082,0.00008251902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9732699,0.01240563,0.002409933,0.0008170055,0.0003553983,0.003739411,0.003158706,0.0001344169,0.003709668],"genre_scores_gemma":[0.9859281,0.002447493,0.00270572,0.0008376551,0.0003545113,0.001804617,0.003807883,0.00004875133,0.002065395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01500392,"threshold_uncertainty_score":0.07934928,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2490517273837873,"score_gpt":0.4762400422636671,"score_spread":0.2271883148798799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}